<DOC>
	<DOCNO>NCT00105482</DOCNO>
	<brief_summary>Weight gain quit smoke important barrier treatment many smoker . This study test drug call naltrexone weight-concerned smoker investigate whether drug improve smoke cessation quit rate minimize post quit weight gain .</brief_summary>
	<brief_title>Targeted Interventions Weight-Concerned Smokers</brief_title>
	<detailed_description>This 6-month randomized , double-blind , placebo control trial 25 mg naltrexone smoke cessation sample 270 male female weight-concerned smoker . Participants also receive transdermal nicotine replacement therapy first 8 week study , begin quit date . Naltrexone study medication start week quit date continue six-month period . Brief behavioral counseling research assessment provide two session prior quit date weekly two week , bi-weekly month every four week thereafter . A follow-up appointment complete 12 month participant ' quit date . The primary outcome six-month point prevalence abstinence post-cessation weight gain continuously abstinent ( even puff ) . Secondary outcome include examination alcohol consumption , evaluation urge , measure smoke cessation success , point prevalence abstinence 12 month , food preference . A number tertiary measure obtain examine predictor smoke cessation , weight gain , naltrexone response .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Concern gain weight quit . This assess use questionnaire provide rating system determine qualified participant . 2 . Age 18 old . 3 . Willingness ability give write consent . 4 . Smoking great 10 cigarette per day least 1 year . 5 . At least one prior attempt stop smoking . 6 . Baseline expire carbonmonoxide level least 10 ppm . 7 . Weigh least 100 lb . 8 . English speaking . 9 . One person per household . 1 . Pregnant nursing woman woman attempt conceive . 2 . Unstable cardiac disease . 3 . History dermatosis . 4 . Current alcohol drug dependence nicotine dependence . 5 . Serious current neurologic , psychiatric medical illness , include significant risk commit suicide base history investigator 's judgment . 6 . Chronic pain condition necessitate opioid treatment ( naltrexone , opioid antagonist , make medication ineffective ) . 7 . History cirrhosis significant hepatocellular injury evidence SGOT SGPT &gt; 3 x normal elevate bilirubin . 8 . Current use smokeless tobacco , pipe , cigar , nicotine gum , patch , nasal spray , inhaler , lozenges . 9 . Patients require concomitant therapy psychotropic drug drug psychotropic component except stable dose Selective Serotonin Reuptake Inhibitor least two month indication Major Depressive Disorder , Premenstrual Syndrome ( PMS ) Premenstrual Dysphoric Disorder ( PMDD ) . 10 . Subjects positive opiate urine drug screen exclude avoid precipitate opiate withdrawal . 11 . Current use opiates . 12 . Currently medically prescribe diet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Tobacco</keyword>
	<keyword>Smoking</keyword>
	<keyword>Weight</keyword>
	<keyword>Weight perception</keyword>
	<keyword>Naltrexone</keyword>
</DOC>